Podcasts about Ovarian cancer

Next Gen in 10 is back!

Thank you for listening to the Stories That Heal Podcast. Please enjoy our Holiday Replays while we take some time to enjoy the holidays! __________ Jenny Kennedy was diagnosed with “incurable” Stage 3C Ovarian Cancer in 2012. Determined to find a way to heal herself she embarked on a journey within to find the answers. She let go of her mind and allowed her intuition to guide her back to a place of great health. By embracing her intuition, she not only overcame a challenging diagnosis, but also transformed her life into one of magic and miracles. Reach Jenny.... www.jennykennedy.co.nz Instagram @jen_kennedy_intuitive Facebook JennyAKennedy __________ To learn more about the 10 Radical Remission Healing Factors, connect with a certified RR coach or join a virtual or in-person workshop visit www.radicalremission.com.   To watch Episode 1 of the Radical Remission Docuseries for free, visit our YouTube channel here.  To purchase the full 10-episode Radical Remission Docuseries visit Hay House Online Learning. To learn more about Radical Remission health coaching with Liz or Karla, Click Here Follow us on Social Media: Facebook  Instagram YouTube _______________

In this episode of Well, Claire and Dr Mariam sit down with writer, speaker, visibility activist and influencer Carly Findlay to talk about her inflammatory skin condition, Ichthyosis. For years, we've watched her deal with the pain and frustration through the low moments and quite a few lovely highs too - always with a fabulous outfit. Through it all, she has been educating, entertaining and allowing us into her space so that we might learn how to help those around us with visible conditions. From the exhaustion of constantly educating strangers to the sheer joy of reclaiming her narrative through fashion, Carly has reminded us of the great lesson that we don’t have to hide away just to make others feel comfortable! In this candid conversation, Carly discusses the intersection of rare disease and the medical system, navigating a cancer diagnosis while managing a complex skin condition, and why - even when experiencing chronic pain or a scary diagnosis - we all deserve to feel f*cking fabulous. So wear the bright dress and take up space! THE END BITS All your health information is in the Well Hub. We understand that conversations about cancer can be difficult, whether you're navigating your own diagnosis, supporting a loved one, or remembering someone you've lost. If today's episode has brought up difficult feelings, please reach out. The Cancer Council offers a confidential support line staffed by specialist nurses, and you can call them on 13 11 20. And if you just need to talk to someone immediately, you can always call Lifeline on 13 11 14. Remember to be kind to yourself, and please don't hesitate to seek support. GET IN TOUCH Sign up to the Well Newsletter to receive your weekly dose of trusted health expertise without the medical jargon. Ask a question of our experts or share your story, feedback, or dilemma - you can send it anonymously here, email here or leave us a voice note here. Ask The Doc: Ask us a question in The Waiting Room. Follow us on Instagram and Tiktok. Support independent women’s media by becoming a Mamamia subscriber CREDITS Hosts: Claire Murphy and Dr Mariam Guest: Carly Findlay Senior Producers: Claire Murphy and Sally Best Audio Producer: Scott Stronach Video Producer: Julian Rosario Social Producer: Elly Moore Mamamia acknowledges the Traditional Owners of the Land we have recorded this podcast on, the Gadigal people of the Eora Nation. We pay our respects to their Elders past and present, and extend that respect to all Aboriginal and Torres Strait Islander cultures.Information discussed in Well. is for education purposes only and is not intended to provide professional medical advice. Listeners should seek their own medical advice, specific to their circumstances, from their treating doctor or health care professional. +++++++++++++++++++++++++++++++++++++++++++++++++++++++++++Support the show: https://www.mamamia.com.au/mplus/See omnystudio.com/listener for privacy information.

Featuring perspectives from Dr Gottfried E Konecny, moderated by Dr Stephen "Fred" Divers, including the following topics:  Updates in Ovarian Cancer (OC) 2025 — Dr Konecny (0:00) Case: A woman in her mid 50s with ovarian cancer and a PALB2 germline mutation — Dr Mulherin (17:15) Case: A woman in her early 60s with Stage IVB fallopian tube carcinoma and a BRCA2 germline mutation — Dr Yannucci (26:27) Case: A woman in her mid 60s with OC and a BRCA2 somatic mutation who develops cytopenias on maintenance olaparib — Dr Lamar (35:47) Case: A woman in her early 70s with HER2 IHC 2+, ER-expressing, FOLR1-positive OC — Dr Warsch (42:54) CE information and select publications

Dr Gottfried E Konecny from the University of California, Los Angeles, summarizes the treatment landscape and reviews relevant clinical datasets for patients with ovarian cancer. CME information and select publications here.

Here’s a structured summary of the interview between Dr. Melanye Maclin and Rushion McDonald: Purpose of the Interview The discussion aimed to educate the audience about the health risks associated with hair care chemicals—including relaxers, dyes, and synthetic hair—and to advocate for safer practices. It also highlighted Dr. Maclin’s pioneering work in hair and skin supplements and her ongoing mission to raise awareness about these issues. Key Takeaways FDA Ban on Hair Chemicals In 2023, the FDA considered banning certain chemicals in hair products due to health risks, but no ban has been implemented yet. These chemicals are linked to breast cancer, uterine cancer, ovarian cancer, and hormone disruption. High-Risk Chemicals Identified Hair Relaxers: Sodium, calcium, guanine, and lithium hydroxide. Hair Dyes: Para-phenylenediamine (especially in permanent dyes). Synthetic Hair: Contains benzene, posing risks of lung cancer and leukemia. Impact on African-American Women African-American women face a 45% higher risk of certain cancers due to combined use of relaxers and dyes. Cultural and aesthetic pressures contribute to continued use despite health risks. Children at Risk Applying relaxers to young girls can cause early puberty, uterine fibroids, infertility, and increased cancer risk. Chemicals penetrate the scalp, enter the bloodstream, and disrupt hormones. Industry Resistance Pushback from salons and manufacturers due to financial interests. Comparison to tobacco and alcohol industries—profit prioritized over health. Solutions & Advice Avoid chemical treatments when possible. If used, protect the entire scalp with petroleum jelly to reduce absorption. Space out relaxer applications (every 8–10 weeks, max 10 minutes for children). Dr. Maclin’s Contributions Launched Bella Nutri supplements (2004 for women, 2008 for men). Advocates internal nutrition for hair and skin health. Website: drmacklin.com and bellabeauproducts.com. Notable Quotes On FDA inaction:“Still to this day, that ban has not occurred… We’re continuously having women going to the next generation of life as a result—next generation cancers.” On cultural pressures:“We’re so into wanting to have a certain look versus wanting to be healthy.” On children’s exposure:“We’ve got to keep chemicals off of little girls’ hair… It’s causing hormone disruption, early puberty, infertility, and increased cancer risk.” On industry resistance:“People care about the green-eyed devil called money… Look at the tobacco industry.” On her mission:“I feel like I’m caring more about someone’s health than they’re caring about their own.” #SHMS #STRAW #BESTSupport the show: https://www.steveharveyfm.com/See omnystudio.com/listener for privacy information.

Here’s a structured summary of the interview between Dr. Melanye Maclin and Rushion McDonald: Purpose of the Interview The discussion aimed to educate the audience about the health risks associated with hair care chemicals—including relaxers, dyes, and synthetic hair—and to advocate for safer practices. It also highlighted Dr. Maclin’s pioneering work in hair and skin supplements and her ongoing mission to raise awareness about these issues. Key Takeaways FDA Ban on Hair Chemicals In 2023, the FDA considered banning certain chemicals in hair products due to health risks, but no ban has been implemented yet. These chemicals are linked to breast cancer, uterine cancer, ovarian cancer, and hormone disruption. High-Risk Chemicals Identified Hair Relaxers: Sodium, calcium, guanine, and lithium hydroxide. Hair Dyes: Para-phenylenediamine (especially in permanent dyes). Synthetic Hair: Contains benzene, posing risks of lung cancer and leukemia. Impact on African-American Women African-American women face a 45% higher risk of certain cancers due to combined use of relaxers and dyes. Cultural and aesthetic pressures contribute to continued use despite health risks. Children at Risk Applying relaxers to young girls can cause early puberty, uterine fibroids, infertility, and increased cancer risk. Chemicals penetrate the scalp, enter the bloodstream, and disrupt hormones. Industry Resistance Pushback from salons and manufacturers due to financial interests. Comparison to tobacco and alcohol industries—profit prioritized over health. Solutions & Advice Avoid chemical treatments when possible. If used, protect the entire scalp with petroleum jelly to reduce absorption. Space out relaxer applications (every 8–10 weeks, max 10 minutes for children). Dr. Maclin’s Contributions Launched Bella Nutri supplements (2004 for women, 2008 for men). Advocates internal nutrition for hair and skin health. Website: drmacklin.com and bellabeauproducts.com. Notable Quotes On FDA inaction:“Still to this day, that ban has not occurred… We’re continuously having women going to the next generation of life as a result—next generation cancers.” On cultural pressures:“We’re so into wanting to have a certain look versus wanting to be healthy.” On children’s exposure:“We’ve got to keep chemicals off of little girls’ hair… It’s causing hormone disruption, early puberty, infertility, and increased cancer risk.” On industry resistance:“People care about the green-eyed devil called money… Look at the tobacco industry.” On her mission:“I feel like I’m caring more about someone’s health than they’re caring about their own.” #SHMS #STRAW #BESTSee omnystudio.com/listener for privacy information.

Here’s a structured summary of the interview between Dr. Melanye Maclin and Rushion McDonald: Purpose of the Interview The discussion aimed to educate the audience about the health risks associated with hair care chemicals—including relaxers, dyes, and synthetic hair—and to advocate for safer practices. It also highlighted Dr. Maclin’s pioneering work in hair and skin supplements and her ongoing mission to raise awareness about these issues. Key Takeaways FDA Ban on Hair Chemicals In 2023, the FDA considered banning certain chemicals in hair products due to health risks, but no ban has been implemented yet. These chemicals are linked to breast cancer, uterine cancer, ovarian cancer, and hormone disruption. High-Risk Chemicals Identified Hair Relaxers: Sodium, calcium, guanine, and lithium hydroxide. Hair Dyes: Para-phenylenediamine (especially in permanent dyes). Synthetic Hair: Contains benzene, posing risks of lung cancer and leukemia. Impact on African-American Women African-American women face a 45% higher risk of certain cancers due to combined use of relaxers and dyes. Cultural and aesthetic pressures contribute to continued use despite health risks. Children at Risk Applying relaxers to young girls can cause early puberty, uterine fibroids, infertility, and increased cancer risk. Chemicals penetrate the scalp, enter the bloodstream, and disrupt hormones. Industry Resistance Pushback from salons and manufacturers due to financial interests. Comparison to tobacco and alcohol industries—profit prioritized over health. Solutions & Advice Avoid chemical treatments when possible. If used, protect the entire scalp with petroleum jelly to reduce absorption. Space out relaxer applications (every 8–10 weeks, max 10 minutes for children). Dr. Maclin’s Contributions Launched Bella Nutri supplements (2004 for women, 2008 for men). Advocates internal nutrition for hair and skin health. Website: drmacklin.com and bellabeauproducts.com. Notable Quotes On FDA inaction:“Still to this day, that ban has not occurred… We’re continuously having women going to the next generation of life as a result—next generation cancers.” On cultural pressures:“We’re so into wanting to have a certain look versus wanting to be healthy.” On children’s exposure:“We’ve got to keep chemicals off of little girls’ hair… It’s causing hormone disruption, early puberty, infertility, and increased cancer risk.” On industry resistance:“People care about the green-eyed devil called money… Look at the tobacco industry.” On her mission:“I feel like I’m caring more about someone’s health than they’re caring about their own.” #SHMS #STRAW #BESTSteve Harvey Morning Show Online: http://www.steveharveyfm.com/See omnystudio.com/listener for privacy information.

In episode 98 of the Summits Podcast, co-hosts Vince Todd, Jr. and Daniel Abdallah are joined by Jesse Monts, Controller at Duncan Supply Company and member of the Heroes Foundation Board of Directors. Tune in as Jesse shares his mother's ovarian cancer journey and how it inspired him to give back to other families facing a cancer diagnosis through the Heroes Foundation.

In this episode of The Jordan Syatt Podcast, I speak with Elana Silber, The CEO of Sharsheret (@sharsheretofficial), a national non-profit organization that helps women and families living with breast and/or ovarian cancer.We discuss:- How Sharsheret fills the gaps in cancer support- Genetic testing and BRCA awareness- How you can get help from Sharsheret for free- How Sharsheret came to be- And more...I hope you enjoy this episode and, if you do, please leave a review on iTunes or Spotify (huge thank you to everyone who has written one so far).Finally, if you've been thinking about joining The Inner Circle but haven't yet... we have hundreds of home and bodyweight workouts for you and you can get them all here: https://www.sfinnercircle.com/

Dr. Linda Duska and Dr. Kathleen Moore discuss key studies in the evolving controversy over radical upfront surgery versus neoadjuvant chemotherapy in advanced ovarian cancer. TRANSCRIPT Dr. Linda Duska: Hello, and welcome to the ASCO Daily News Podcast. I am your guest host, Dr. Linda Duska. I am a professor of obstetrics and gynecology at the University of Virginia School of Medicine.  On today's episode, we will explore the management of advanced ovarian cancer, specifically with respect to a question that has really stirred some controversy over time, going all the way back more than 20 years: Should we be doing radical upfront surgery in advanced ovarian cancer, or should we be doing neoadjuvant chemotherapy? So, there was a lot of hype about the TRUST study, also called ENGOT ov33/AGO-OVAR OP7, a Phase 3 randomized study that compares upfront surgery with neoadjuvant chemotherapy followed by interval surgery. So, I want to talk about that study today. And joining me for the discussion is Dr. Kathleen Moore, a professor also of obstetrics and gynecology at the University of Oklahoma and the deputy director of the Stephenson Cancer Center, also at the University of Oklahoma Health Sciences.  Dr. Moore, it is so great to be speaking with you today. Thanks for doing this. Dr. Kathleen Moore: Yeah, it's fun to be here. This is going to be fun. Dr. Linda Duska: FYI for our listeners, both of our full disclosures are available in the transcript of this episode.  So let's just jump right in. We already alluded to the fact that the TRUST study addresses a question we have been grappling with in our field. Here's the thing, we have four prior randomized trials on this exact same topic. So, share with me why we needed another one and what maybe was different about this one? Dr. Kathleen Moore: That is, I think, the key question. So we have to level-set kind of our history. Let's start with, why is this even a question? Like, why are we even talking about this today? When we are taking care of a patient with newly diagnosed ovarian cancer, the aim of surgery in advanced ovarian cancer ideally is to prolong a patient's likelihood of disease-free survival, or if you want to use the term "remission," you can use the term "remission." And I think we can all agree that our objective is to improve overall survival in a way that also does not compromise her quality of life through surgical complications, which can have a big effect. The standard for many decades, certainly my entire career, which is now over 20 years, has been to pursue what we call primary cytoreductive surgery, meaning you get a diagnosis and we go right to the operating room with a goal of achieving what we call "no gross residual." That is very different – in the olden days, you would say "optimal" and get down to some predefined small amount of tumor. Now, the goal is you remove everything you can see.  The alternative strategy to that is neoadjuvant chemotherapy followed by interval cytoreductive surgery, and that has been the, quote-unquote, "safer" route because you chemically cytoreduce the cancer, and so, the resulting surgery, I will tell you, is not necessarily easy at all. It can still be very radical surgeries, but they tend to be less radical, less need for bowel resections, splenectomy, radical procedures, and in a short-term look, would be considered safer from a postoperative consideration. Dr. Linda Duska: Well, and also maybe more likely to be successful, right? Because there's less disease, maybe, theoretically. Dr. Kathleen Moore: More likely to be successful in getting to no gross residual. Dr. Linda Duska: Right. Yeah, exactly. Dr. Kathleen Moore: I agree with that. And so, so if the end game, regardless of timing, is you get to no gross residual and you help a patient and there's no difference in overall survival, then it's a no-brainer. We would not be having this conversation. But there remains a question around, while it may be more likely to get to no gross residual, it may be, and I think we can all agree, a less radical, safer surgery, do you lose survival in the long term by this approach? This has become an increasing concern because of the increase in rates of use of neoadjuvant, not only in this country, but abroad. And so, you mentioned the four prior studies. We will not be able to go through them completely. Dr. Linda Duska: Let's talk about the two modern ones, the two from 2020 because neither one of them showed a difference in overall survival, which I think we can agree is, at the end of the day, yes, PFS would be great, but OS is what we're looking for. Dr. Kathleen Moore: OS is definitely what we're looking for. I do think a marked improvement in PFS, like a real prolongation in disease-free survival, for me would be also enough. A modest improvement does not really cut it, but if you are really, really prolonging PFS, you should see that-  Dr. Linda Duska: -manifest in OS. Dr. Kathleen Moore: Yeah, yeah. Okay. So let's talk about the two modern ones. The older ones are EORTC and CHORUS, which I think we've talked about. The two more modern ones are SCORPION and JCOG0602. So, SCORPION was interesting. SCORPION was a very small study, though. So one could say it's underpowered. 170 patients. And they looked at only patients that were incredibly high risk. So, they had to have a Fagotti score, I believe, of over 9, but they were not looking at just low volume disease. Like, those patients were not enrolled in SCORPION. It was patients where you really were questioning, "Should I go to the OR or should I do neoadjuvant? Like, what's the better thing?" It is easy when it's low volume. You're like, "We're going." These were the patients who were like, "Hm, you know, what should I do?" High volume. Patients were young, about 55. The criticism of the older studies, there are many criticisms, but one of them is that, the criticism that is lobbied is that they did not really try. Whatever surgery you got, they did not really try with median operative times of 180 minutes for primary cytoreduction, 120 for neoadjuvant. Like, you and I both know, if you're in a big primary debulking, you're there all day. It's 6 hours. Dr. Linda Duska: Right, and there was no quality control for those studies, either. Dr. Kathleen Moore: No quality control. So, SCORPION, they went 451-minute median for surgery. Like, they really went for it versus four hours and then 253 for the interval, 4 hours. They really went for it on both arms. Complete gross resection was achieved in 50% of the primary cytoreduced. So even though they went for it with these very long surgeries, they only got to the goal half the time. It was almost 80% in the interval group. So they were more successful there. And there was absolutely no difference in PFS or OS. They were right about 15 months PFS, right about 40 months OS.  JCOG0602, of course, done in Japan, a big study, 300 patients, a little bit older population. Surprisingly more stage IV disease in this study than were in SCORPION. SCORPION did not have a lot of stage IV, despite being very bulky tumors. So a third of patients were stage IV. They also had relatively shorter operative times, I would say, 240 minutes for primary, 302 for interval. So still kind of short. Complete gross resection was not achieved very often. 30% of primary cytoreduction. That is not acceptable. Dr. Linda Duska: Well, so let's talk about TRUST. What was different about TRUST? Why was this an important study for us to see? Dr. Kathleen Moore: So the criticism of all of these, and I am not trying to throw shade at anyone, but the criticism of all of these is if you are putting surgery to the test, you are putting the surgeon to the test. And you are assuming that all surgeons are trained equally and are willing to do what it takes to get someone to no gross residual. Dr. Linda Duska: And are in a center that can support the post-op care for those patients. Dr. Kathleen Moore: Which can be ICU care, prolonged time. Absolutely. So when you just open these broadly, you're assuming everyone has the surgical skills and is comfortable doing that and has backup. Everybody has an ICU. Everyone has a blood bank, and you are willing to do that. And that assumption could be wrong. And so what TRUST said is, "Okay, we are only going to open this at centers that have shown they can achieve a certain level of primary cytoreduction to no gross residual disease." And so there was quality criteria. It was based on – it was mostly a European study – so ESGO criteria were used to only allow certified centers to participate. They had to have a surgical volume of over 36 cytoreductive surgeries per year. So you could not be a low volume surgeon. Your complete resection rates that were reported had to be greater than 50% in the upfront setting. I told you on the JCOG, it was 30%. Dr. Linda Duska: Right. So these were the best of the best. This was the best possible surgical situation you could put these patients in, right? Dr. Kathleen Moore: Absolutely. And you support all the things so you could mitigate postoperative complications as well. Dr. Linda Duska: So we are asking the question now again in the ideal situation, right? Dr. Kathleen Moore: Right. Dr. Linda Duska: Which, we can talk about, may or may not be generalizable to real life, but that's a separate issue because we certainly don't have those conditions everywhere where people get cared for with ovarian cancer. But how would you interpret the results of this study? Did it show us anything different? Dr. Kathleen Moore: I am going to say how we should interpret it and then what I am thinking about. It is a negative study. It was designed to show improvement in overall survival in these ideal settings in patients with FIGO stage IIIB and C, they excluded A, these low volume tumors that should absolutely be getting surgery. So FIGO stage IIIB and C and IVA and B that were fit enough to undergo radical surgery randomized to primary cytoreduction or neoadjuvant with interval, and were all given the correct chemo. Dr. Linda Duska: And they were allowed bevacizumab and PARP, also. They could have bevacizumab and PARP. Dr. Kathleen Moore: They were allowed bevacizumab and PARP. Not many of them got PARP, but it was distributed equally, so that would not be a confounder. And so that was important. Overall survival is the endpoint. It was a big study. You know, it was almost 600 patients. So appropriately powered. So let's look at what they reported. When they looked at the patients who were enrolled, this is a large study, almost 600 patients, 345 in the primary cytoreductive arm and 343 in the neoadjuvant arm. Complete resection in these patients was 70% in the primary cytoreductive arm and 85% in the neoadjuvant arm. So in both arms, it was very high. So your selection of site and surgeon worked. You got people to their optimal outcome. So that is very different than any other study that has been reported to date. But what we saw when we looked at overall survival was no statistical difference. The median was, and I know we do not like to talk about medians, but the median in the primary cytoreductive arm was 54 months versus 48 months in the neoadjuvant arm with a hazard ratio of 0.89 and, of course, the confidence interval crossed one. So this is not statistically significant. And that was the primary endpoint. Dr. Linda Duska: I know you are getting to this. They did look at PFS, and that was statistically significant, but to your point about what are we looking for for a reasonable PFS difference? It was about two months difference. When I think about this study, and I know you are coming to this, what I thought was most interesting about this trial, besides the fact that the OS, the primary endpoint was negative, was the subgroup analyses that they did. And, of course, these are hypothesis-generating only. But if you look at, for example, specifically only the stage III group, that group did seem to potentially, again, hypothesis generating, but they did seem to benefit from upfront surgery.  And then one other thing that I want to touch on before we run out of time is, do we think it matters if the patient is BRCA germline positive? Do we think it matters if there is something in particular about that patient from a biomarker standpoint that is different? I am hopeful that more data will be coming out of this study that will help inform this. Of course, unpowered, hypothesis-generating only, but it's just really interesting. What do you think of their subset analysis? Dr. Kathleen Moore: Yeah, I think the subsets are what we are going to be talking about, but we have to emphasize that this was a negative trial as designed. Dr. Linda Duska: Absolutely. Yes. Dr. Kathleen Moore: So we cannot be apologists and be like, "But this or that." It was a negative trial as designed. Now, I am a human and a clinician, and I want what is best for my patients. So I am going to, like, go down the path of subset analyses. So if you look at the stage III tumors that got complete cytoreduction, which was 70% of the cases, your PFS was almost 28 months versus 21.8 months. Dr. Linda Duska: Yes, it becomes more significant. Dr. Kathleen Moore: Yeah, that hazard ratio is 0.69. Again, it is a subset. So even though the P value here is statistically significant, it actually should not have a P value because it is an exploratory analysis. So we have to be very careful. But the hazard ratio is 0.69. So the hypothesis is in this setting, if you're stage III and you go for it and you get someone to no gross residual versus an interval cytoreduction, you could potentially have a 31% reduction in the rate of progression for that patient who got primary cytoreduction. And you see a similar trend in the stage III patients, if you look at overall survival, although the post-progression survival is so long, it's a little bit narrow of a margin.  But I do think there are some nuggets here that, one of our colleagues who is really one of the experts in surgical studies, Dr. Mario Leitao, posted this on X, and I think it really resonated after this because we were all saying, "But what about the subsets?" He is like, "It's a negative study." But at the end of the day, you are going to sit with your patient. The patient should be seen by a GYN oncologist or surgical oncologist with specialty in cytoreduction and a medical oncologist, you know, if that person does not give chemo, and the decision should be made about what to do for that individual patient in that setting. Dr. Linda Duska: Agreed. And along those lines, if you look carefully at their data, the patients who had an upfront cytoreduction had almost twice the risk of having a stoma than the patients who had an interval cytoreduction. And they also had a higher risk of needing to have a bowel resection. The numbers were small, but still, when you look at the surgical complications, as you've already said, they're higher in the upfront group than they are in the interval group. That needs to be taken into account as well when counseling a patient, right? When you have a patient in front of you who says to you, "Dr. Moore, you can take out whatever you want, but whatever you do, don't make me a bag." As long as the patient understands what that means and what they're asking us to do, I think that we need to think about that. Dr. Kathleen Moore: I think that is a great point. And I have definitely seen in our practice, patients who say, "I absolutely would not want an ostomy. It's a nonstarter for me." And we do make different decisions. And you have to just say, "That's the decision we've made," and you kind of move on, and you can't look back and say, "Well, I wish I would have, could have, should have done something else." That is what the patient wants. Ultimately, that patient, her family, autonomous beings, they need to be fully counseled, and you need to counsel that patient as to the site that you are in, her volume of disease, and what you think you can achieve. In my opinion, a patient with stage III cancer who you have the site and the capabilities to get to no gross residual should go to the OR first. That is what I believe. I do not anymore think that for stage IV. I think that this is pretty convincing to me that that is probably a harmful thing. However, I want you to react to this. I think I am going to be a little unpopular in saying this, but for me, one of the biggest take-homes from TRUST was that whether or not, and we can talk about the subsets and the stage III looked better, and I think it did, but both groups did really well. Like, really well. And these were patients with large volume disease. This was not cherry-picked small volume stage IIIs that you could have done an optimal just by doing a hysterectomy. You know, these were patients that needed radical surgery. And both did well. And so what it speaks to me is that anytime you are going to operate on someone with ovary, whether it be frontline, whether it be a primary or interval, you need a high-volume surgeon. That is what I think this means to me. Like, I would want high volume surgeon at a center that could do these surgeries, getting that patient, my family member, me, to no gross residual. That is important. And you and I are both in training centers. I think we ought to take a really strong look at, are we preparing people to do the surgeries that are necessary to get someone to no gross residual 70% and 85% of the time? Dr. Linda Duska: We are going to run out of time, but I want to address that and ask you a provocative question. So, I completely agree with what you said, that surgery is important. But I also think one of the reasons these patients in this study did so well is because all of the incredible new therapies that we have for patients. Because OS is not just about surgery. It is about surgery, but it is also about all of the amazing new therapies we have that you and others have helped us to get through clinical research. And so, how much of that do you think, like, for example, if you look at the PFS and OS rates from CHORUS and EORTC, I get it that they're, that they're not the same. It's different patients, different populations, can't do cross-trial comparisons. But the OS, as you said, in this study was 54 months and 48 months, which is, compared to 2010, we're doing much, much better. It is not just the surgery, it is also all the amazing treatment options we have for these patients, including PARP, including MIRV, including lots of other new therapies. How do you fit that into thinking about all of this? Dr. Kathleen Moore: I do think we are seeing, and we know this just from epidemiologic data that the prevalence of ovarian cancer in many of the countries where the study was done is increasing, despite a decrease in incidence. And why is that? Because people are living longer. Dr. Linda Duska: People are living longer, yeah. Dr. Kathleen Moore: Which is phenomenal. That is what we want. And we do have, I think, better supportive care now. PARP inhibitors in the frontline, which not many of these patients had. Now some of them, this is mainly in Europe, will have gotten them in the first maintenance setting, and I do think that impacts outcome. We do not have that data yet, you know, to kind of see what, I would be really interested to see. We do not do this well because in ovarian cancer, post-progression survival can be so long, we do not do well of tracking what people get when they come off a clinical trial to see how that could impact – you know, how many of them got another surgery? How many of them got a PARP? I think this group probably missed the ADC wave for the most part, because this, mirvetuximab is just very recently available in Europe. Dr. Linda Duska: Unless they were on trial. Dr. Kathleen Moore: Unless they were on trial. But I mean, I think we will have to see. 600 patients, I would bet a lot of them missed the ADC wave. So, I do not know that we can say we know what drove these phenomenal – these are some of the best curves we've seen outside of BRCA. And then coming back to your point about the BRCA population here, that is a really critical question that I do not know that we're ever going to answer. There have been hypotheses around a tumor that is driven by BRCA, if you surgically cytoreduced it, and then chemically cytoreduced it with chemo, and so you're starting PARP with nothing visible and likely still homogeneous clones. Is that the group we cured? And then if you give chemo first before surgery, it allows more rapid development of heterogeneity and more clonal evolution that those are patients who are less likely to be cured, even if they do get cytoreduced to nothing at interval with use of PARP inhibitor in the front line. That is a question that many have brought up as something we would like to understand better. Like, if you are BRCA, should you always just go for it or not? I do not know that we're ever going to really get to that. We are trying to look at some of the other studies and just see if you got neoadjuvant and you had BRCA, was anyone cured? I think that is a question on SOLO1 I would like to know the answer to, and I don't yet, that may help us get to that. But that's sort of something we do think about. You should have a fair number of them in TRUST. It wasn't a stratification factor, as I remember. Dr. Linda Duska: No, it wasn't. They stratified by center, age, and ECOG status Dr. Kathleen Moore: So you would hope with randomization that you would have an equal number in each arm. And they may be able to pull that out and do a very exploratory look. But I would be interested to see just completely hypothesis-generating what this looks like for the patients with BRCA, and I hope that they will present that. I know they're busy at work. They have translational work. They have a lot pending with TRUST. It's an incredibly rich resource that I think is going to teach us a lot, and I am excited to see what they do next. Dr. Linda Duska: So, outside of TRUST, we are out of time. I just want to give you a moment if there were any other messages that you want to share with our listeners before we wrap up. Dr. Kathleen Moore: It's an exciting time to be in GYN oncology. For so long, it was just chemo, and then the PARP inhibitors nudged us along quite a bit. We did move more patients, I believe, to the cure fraction. When we ultimately see OS, I think we'll be able to say that definitively, and that is exciting. But, you know, that is the minority of our patients. And while HRD positive benefits tremendously from PARP, I am not as sure we've moved as many to the cure fraction. Time will tell. But 50% of our patients have these tumors that are less HRD. They have a worse prognosis. I think we can say that and recur more quickly. And so the advent of these antibody-drug conjugates, and we could name 20 of them in development in GYN right now, targeting tumor-associated antigens because we're not really driven by mutations other than BRCA. We do not have a lot of things to come after. We're not lung cancer. We are not breast cancer. But we do have a lot of proteins on the surface of our cancers, and we are finally able to leverage that with some very active regimens. And we're in the early phases, I would say, of really understanding how best to use those, how best to position them, and which one to select for whom in a setting where there is going to be obvious overlap of the targets. So we're going to be really working this problem. It is a good problem. A lot of drugs that work pretty well. How do you individualize for a patient, the patient in front of you with three different markers? How do you optimize it? Where do you put them to really prolong survival? And then we finally have cell surface. We saw at ASCO, CDK2 come into play here for the first time, we've got a cell cycle inhibitor. We've been working on WEE1 and ATR for a long time. CDK2s may hit. Response rates were respectable in a resistant population that was cyclin E overexpressing. We've been working on that biomarker for a long time with a toxicity profile that was surprisingly clean, which I like to see for our patients. So that is a different platform. I think we have got bispecifics on the rise. So there is a pipeline of things behind the ADCs, which is important because we need more than one thing, that makes me feel like in the future, I am probably not going to be using doxil ever for platinum-resistant disease. So, I am going to be excited to retire some of those things. We will say, "Remember when we used to use doxil for platinum-resistant disease?" Dr. Linda Duska: I will be retired by then, but thanks for that thought. Dr. Kathleen Moore: I will remind you. Dr. Linda Duska: You are right. It is such an incredibly exciting time to be taking care of ovarian cancer patients with all the opportunities.  And I want to thank you for sharing your valuable insights with us on this podcast today and for your great work to advance care for patients with GYN cancers. Dr. Kathleen Moore: Likewise. Thanks for having me. Dr. Linda Duska: And thank you to our listeners for your time today. You will find links to the TRUST study and other studies discussed today in the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers:   Dr. Linda Duska  @Lduska Dr. Kathleen Moore Follow ASCO on social media:     @ASCO on X (formerly Twitter) ASCO on Bluesky   ASCO on Facebook     ASCO on LinkedIn     Disclosures of Potential Conflicts of Interest:    Dr. Linda Duska:   Consulting or Advisory Role: Regeneron, Inovio Pharmaceuticals, Merck, Ellipses Pharma  Research Funding (Inst.): GlaxoSmithKline, Millenium, Bristol-Myers Squibb, Aeterna Zentaris, Novartis, Abbvie, Tesaro, Cerulean Pharma, Aduro Biotech, Advaxis, Ludwig Institute for Cancer Research, Leap Therapeutics  Patents, Royalties, Other Intellectual Property: UptToDate, Editor, British Journal of Ob/Gyn  Dr. Kathleen Moore: Leadership: GOG Partners, NRG Ovarian Committee Chair Honoraria: Astellas Medivation, Clearity Foundation, IDEOlogy Health, Medscape, Great Debates and Updates, OncLive/MJH Life Sciences, MD Outlook, Curio Science, Plexus, University of Florida, University of Arkansas for Medical Sciences, Congress Chanel, BIOPHARM, CEA/CCO, Physician Education Resource (PER), Research to Practice, Med Learning Group, Peerview, Peerview, PeerVoice, CME Outfitters, Virtual Incision Consulting/Advisory Role: Genentech/Roche, Immunogen, AstraZeneca, Merck, Eisai, Verastem/Pharmacyclics, AADi, Caris Life Sciences, Iovance Biotherapeutics, Janssen Oncology, Regeneron, zentalis, Daiichi Sankyo Europe GmbH, BioNTech SE, Immunocore, Seagen, Takeda Science Foundation, Zymeworks, Profound Bio, ADC Therapeutics, Third Arc, Loxo/Lilly, Bristol Myers Squibb Foundation, Tango Therapeutics, Abbvie, T Knife, F Hoffman La Roche, Tubulis GmbH, Clovis Oncology, Kivu, Genmab/Seagen, Kivu, Genmab/Seagen, Whitehawk, OnCusp Therapeutics, Natera, BeiGene, Karyopharm Therapeutics, Day One Biopharmaceuticals, Debiopharm Group, Foundation Medicine, Novocure Research Funding (Inst.): Mersana, GSK/Tesaro, Duality Biologics, Mersana, GSK/Tesaro, Duality Biologics, Merck, Regeneron, Verasatem, AstraZeneca, Immunogen, Daiichi Sankyo/Lilly, Immunocore, Torl Biotherapeutics, Allarity Therapeutics, IDEAYA Biosciences, Zymeworks, Schrodinger Other Relationship (Inst.): GOG Partners

Leila Nathoo sits in for Naga Munchetty. She speaks to Hannah Lane about being diagnosed with ovarian cancer and her life living with the condition. She's also joined by regular experts Dr Nighat Arif and Dr Christine Ekechi. First broadcast on BBC 5 Live on 18 November 2025

Morning Prayer (Binding Ourselves to Lord, Breast & Ovarian Cancer)  #prayer #morningprayer #pray #jesus #god #holyspirit #aimingforjesus #healing #peace #love #bible #bindonearth #bindinheaven #breastcancer #ovariancancer Thank you for listening, our heart's prayer is for you and I to walk daily with Jesus, our joy and peace aimingforjesus.com YouTube Channel https://www.youtube.com/@aimingforjesus5346 Instagram https://www.instagram.com/aiming_for_jesus/ Threads https://www.threads.com/@aiming_for_jesus X https://x.com/AimingForJesus Tik Tok https://www.tiktok.com/@aiming.for.jesus

In this episode, Fred interviews Jennifer Hall - Disciples of Christ Worship Leader, Music Educator & Reiki Master. Learn more at: https://www.reflectyourlight.com/ Meet Jennifer Hall: Hi! My name is Jennifer. I have been an elementary music teacher in the Kansas City, Kansas Public School District for 24 years. I was honored in 2019 by my school district to be chosen as the elementary teacher of the year. I have dedicated my entire career to bringing the joy of music to inner-city children and found a lot of fulfillment and life-purpose through the blessings of that job. In 2017, I was attuned to Reiki by my sister, Mary Bolan, who is a Disciples of Christ Christian Church Minister and a Reiki Master. During my Level II attunement, I had the most spiritual experience of my life during which I knew that offering Reiki Healing to others is my true calling. I made it my goal to perform 100 free reiki healing sessions so that I could truly hone my skills as I learned. I asked my “guinea pigs” to give me feedback as I developed my own style. After I felt confident in my abilities, friends and family started sending me referrals and I continued to offer healing through word-of-mouth (no website, business name etc.) only. In the fall of 2020, I started hearing the Holy Spirit speak to me that it was time to devote more time to my healing business so I quit teaching full-time and now teach Elementary Strings (violins, violas and cellos) 3 days a week and see clients two days a week plus occasional evenings and weekends. In 2014, I had treatment for Ovarian Cancer and used Integrative as well as Traditional Medicine to help me fully heal from that often-deadly cancer. At the time, I didn't know about Reiki but I received massage, acupuncture, BodyTalk, chiropractic adjustments and worked with an Integrative Medicine M.D. who gave me Vitamin C infusions as well as nutritional and energetic supports. Many, many people prayed for me and supported me through that season. I learned a lot about worthiness, intentions, affirmations and faith. I am grateful that we have many healing modalities available to us today. This is a unique time in history to benefit from Eastern and Western medical and spiritual healing traditions.

In this episode, Dr Rachel Grisham and Dr Kathleen Moore discuss newly approved treatments for low-grade serous ovarian cancer (LGSOC) and how recent research has transformed the therapeutic landscape for these patients, including:Molecular distinctions between low-grade and high-grade serous ovarian cancer that can guide therapy selectionThe recently approved targeted therapy combination regimen of avutometinib and defactinib for KRAS-mutant LGSOC (RAMP 201)Promising future directions for patients with LGSOC based on ongoing studies such as RAMP 301 and CHAMELEON Presenters:Rachel Grisham, MDSection Head of Ovarian CancerMemorial Sloan Kettering Cancer CenterDirector Gynecologic Medical Oncology, MSKCC WestchesterNew York, New YorkKathleen N. Moore, MD, MS, FASCODeputy Director and Cancer Therapeutics Co-LeadStephenson Cancer Center at the University of OklahomaProfessorDepartment of OB/GynASCO BODOklahoma City, Oklahoma Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Editor’s Choice: Surgical complexity and scope of procedures necessary after neoadjuvant chemotherapy for primary ovarian cancer Hosted by:Ursula Matulonis, MD, Associate Editor of Gynecologic OncologyFeaturing: William Cliby, Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, USAChiara Ainio, Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, USAOliver Zivanovic, Clinic for Gynecology and Obstetrics, Heidelberg University Hospital, Heidelberg, Germany

Dr. Stacy Lindborg, President and CEO of IMUNON, has developed a DNA-based immunotherapy candidate for the treatment of ovarian cancer. This therapy works by administering the drug, which utilizes IL-12, a powerful anti-cancer cytokine, directly into the cavity where the cancer resides, thereby affecting the tumor microenvironment. Trials are showing that the drug can produce significant life extension when used in combination with standard chemotherapy. Stacy explains, "There are about 300,000 women who are newly diagnosed with advanced ovarian cancer every year, about 20,000 in the US, and the frontline standard of care hasn't seen a change in the treatment in about 25 years. So this is for newly diagnosed women. The very first treatment that they would have, which we call frontline treatment, is a platinum-based chemotherapy. So carboplatin and Paclitaxel are both administered through IV over an hour for carboplatin, about three hours for Paclitaxel. So most women go directly to chemotherapy and then surgery, and then chemotherapy. Some women will go straight to surgery and then have this chemotherapy afterwards."   "Our approach is a DNA-based immunotherapy candidate that we have in Phase 3. We refer to the lead candidate as IMNN-001, and this is a non-viral nanoparticle that is administered directly into the cavity of interest. So, what we call the micro-tumor environment is the peritoneal cavity, where the cancer actually resides, and it's delivered through a catheter. And it basically has a very powerful anti-cancer fighting cytokine, IL-12, that is encoded in this immunotherapy. And it causes the cells that are within each woman's body, both cancer and non-cancer alike, to start producing activities that will help fight these complex cancer cells that exist."  #IMUNON #OvarianCancer #DNABasedImmunotherapy #WomensHealth #CancerAwareness  imunon.com Download the transcript here

Dr. Stacy Lindborg, President and CEO of IMUNON, has developed a DNA-based immunotherapy candidate for the treatment of ovarian cancer. This therapy works by administering the drug, which utilizes IL-12, a powerful anti-cancer cytokine, directly into the cavity where the cancer resides, thereby affecting the tumor microenvironment. Trials are showing that the drug can produce significant life extension when used in combination with standard chemotherapy. Stacy explains, "There are about 300,000 women who are newly diagnosed with advanced ovarian cancer every year, about 20,000 in the US, and the frontline standard of care hasn't seen a change in the treatment in about 25 years. So this is for newly diagnosed women. The very first treatment that they would have, which we call frontline treatment, is a platinum-based chemotherapy. So carboplatin and Paclitaxel are both administered through IV over an hour for carboplatin, about three hours for Paclitaxel. So most women go directly to chemotherapy and then surgery, and then chemotherapy. Some women will go straight to surgery and then have this chemotherapy afterwards."   "Our approach is a DNA-based immunotherapy candidate that we have in Phase 3. We refer to the lead candidate as IMNN-001, and this is a non-viral nanoparticle that is administered directly into the cavity of interest. So, what we call the micro-tumor environment is the peritoneal cavity, where the cancer actually resides, and it's delivered through a catheter. And it basically has a very powerful anti-cancer fighting cytokine, IL-12, that is encoded in this immunotherapy. And it causes the cells that are within each woman's body, both cancer and non-cancer alike, to start producing activities that will help fight these complex cancer cells that exist."  #IMUNON #OvarianCancer #DNABasedImmunotherapy #WomensHealth #CancerAwareness  imunon.com Listen to the podcast here

In this episode, Kathleen N. Moore, MD, MS, FASCO, and Isabelle Ray-Coquard, MD, PhD, discuss the emerging role of CDH6-targeting antibody–drug conjugates (ADCs) for ovarian cancer, including:Results of the phase I trial of raludotatug deruxtecan (R-DXd) in ovarian cancerResults of the phase II REJOICE-Ovarian01 study in patients with platinum-resistant diseaseHow R-DXd may be incorporated into the treatment paradigmOther investigational CDH6-targeting ADCs: CUSP06, SIM0505Presenters:Kathleen N. Moore, MD, MS, FASCO Deputy Director and Cancer Therapeutics Co-LeadStephenson Cancer Center at the University of OklahomaProfessorDepartment of OB/GynASCO BODOklahoma City, OklahomaIsabelle Ray-Coquard, MD, PhD President of the Gineco GroupCentre Leon BérardReshape Lab Inserm u1290Université Claude Bernard Lyon EstLyon, FranceContent based on an online CME program supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.Link to full program: https://bit.ly/43PXoeP Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Welcome to the Oncology Brothers podcast! In this episode, we are joined by Dr. Sharyn Lewin, the Director of Gynecology Oncology at Holy Name Medical Center, to explore the evolving treatment landscape of ovarian cancer. Join us as we discuss: • The importance of surgical staging and debulking surgery in ovarian cancer treatment. • The role of neoadjuvant chemotherapy and the significance of germline testing. • Current systemic treatment paradigms, including the use of PARP inhibitors and Bevacizumab. • Insights into the management of refractory disease and the latest options available for patients. • The impact of biomarker testing and the importance of understanding HRD status. Dr. Lewin shared her expertise on the latest clinical data, treatment strategies, and the implications of testing for patients and their families. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell to stay updated on our upcoming episodes, including our next discussion on endometrial cancer! #OvarianCancer #PARPinhibitors #GermlineTesting #GynOnc #OncologyBrothers #MaintenanceTherapy #PersonalizedMedicine

Prof. Samuel Antwi Oppong joins us again as we talk about explore why ovarian cancer is called the silent killer, often diagnosed late, risk factors, genetic predisposition (BRCA genes), symptoms to watch for, and treatment approaches.

Prof. Samuel Antwi Oppong joins us again as we talk about explore why ovarian cancer is called the silent killer, often diagnosed late, risk factors, genetic predisposition (BRCA genes), symptoms to watch for, and treatment approaches.

What are the subtle signs of gynae cancers we might be dismissing as something else? Could the type of pan you cook with help your iron deficiency? And are your allergy medications causing dryness... down there? We know hearing the word 'cancer' can be a frightening experience. But facing that fear with facts is the first step. We’re here to arm you with the information you need – from spotting subtle symptoms to understanding risk factors – so you can feel empowered to advocate for your own health and persist in getting the answers you deserve. In this episode, we talk to medical oncologist Professor Clare Scott, Chair of Australia New Zealand Gynaecological Oncology Group and one of Australia’s leading cancer researchers and clinicians. We discuss the three major types of gynae cancers: ovarian, endometrial and cervical, why your endo and PCOS aren’t cause for cancer concern and the effect of ovarian cancer on your fertility. We also talk about why you might be iron deficient and the simple kitchen tools that could help boost your iron levels, especially if you don't eat a lot of red meat. Plus, Dr. Mariam explains misconceptions around the HPV virus and the importance of self-collected HPV testing in Australia's mission to eliminate cervical cancer. THE END BITS All your health information is in the Well Hub. We understand that conversations about cancer can be difficult, whether you're navigating your own diagnosis, supporting a loved one, or remembering someone you've lost. If today's episode has brought up difficult feelings, please reach out. The Cancer Council offers a confidential support line staffed by specialist nurses, and you can call them on 13 11 20. For more specific information on the topics we discussed today, organisations like Australian Gynaecological Cancer Foundation, Ovarian Cancer Australia and the Australian Cervical Cancer Foundation provide incredible support and resources for patients and their families. And if you just need to talk to someone immediately, you can always call Lifeline on 13 11 14. Remember to be kind to yourself, and please don't hesitate to seek support. GET IN TOUCH Sign up to the Well Newsletter to receive your weekly dose of trusted health expertise without the medical jargon. Ask a question of our experts or share your story, feedback, or dilemma - you can send it anonymously here, email here or leave us a voice note here. Ask The Doc: Ask us a question in The Waiting Room. Follow us on Instagram and Tiktok. Support independent women’s media by becoming a Mamamia subscriber CREDITS Hosts: Claire Murphy and Dr Mariam Guest: Professor Clare Scott Senior Producers: Claire Murphy and Sally Best Audio Producer: Scott Stronach Video Producer: Julian Rosario Social Producer: Elly Moore Mamamia acknowledges the Traditional Owners of the Land we have recorded this podcast on, the Gadigal people of the Eora Nation. We pay our respects to their Elders past and present, and extend that respect to all Aboriginal and Torres Strait Islander cultures.Information discussed in Well. is for education purposes only and is not intended to provide professional medical advice. Listeners should seek their own medical advice, specific to their circumstances, from their treating doctor or health care professional.Support the show: https://www.mamamia.com.au/mplus/See omnystudio.com/listener for privacy information.

Evening Prayer (night fears, broken family, ovarian cancer, find the right church) #pray #prayer #Jesus #god #holyspirit #EveningPrayer #nightterror #LordOfAllCreation #GodOverAll #PeacefulRest #NoFearInChrist #FamilyRestoration #ovariancancer #HealingPrayer #TruthChurch #LivingTheWord Thank you for listening, our heart's prayer is for you and I to walk daily with Jesus, our joy and peace aimingforjesus.com YouTube Channel https://www.youtube.com/@aimingforjesus5346 Instagram https://www.instagram.com/aiming_for_jesus/ Threads https://www.threads.com/@aiming_for_jesus X https://x.com/AimingForJesus Tik Tok https://www.tiktok.com/@aiming.for.jesus

In this episode of the Out of the Fire podcast, host Trisha speaks with Lynn Whitt, an inspiring 83-year-old ovarian cancer survivor who has battled the disease since her diagnosis at age 67. Lynn shares her journey through 150 rounds of chemotherapy, the challenges she faced, and the importance of finding motivation to keep fighting. The conversation highlights the role of compassion in healthcare, the significance of support systems, and the advancements in cancer treatment that have made a difference in patients' lives. Lynn's story serves as a beacon of hope and resilience for anyone facing similar struggles. Chapters 00:00 The Diagnosis Journey 06:47 The Role of Family and Support 11:43 Lessons Learned and Advice for Others 16:37 Hope and Technological Advances in Treatment 21:54 Finding Your Why in Difficult Times 23:13 The Importance of Support and Resources www.trishafraley.com www.madetowalkthroughfire.com

Examining the claim that cabbage family vegetables are bad for the thyroid; Walmart announces sweeping move to reformulate its products without synthetic dyes, sketchy additives; Under Congressional questioning, Google admits to censoring contrary narratives on YouTube during Covid; Children garner psychological benefits from grandparent time; J&J fined nearly $1 billion in landmark talc baby powder lawsuit; Humans are among the few animals who can't make their own vitamin C—why that may be a good thing.

Support Connection's Annual Support-A-Walk for Breast & Ovarian Cancer is community event dedicated to raising awareness about the needs of those living with breast, ovarian, or any gynecological cancer. The 2025 walk took place on Sunday, October 5, at FDR State Park in Yorktown Heights, NY, where everyone was invited to “Walk With Us, Wherever You Are.” The walk helps fund Support Connection's free and vital services, including one-on-one peer counseling, support groups, educational and wellness programs, and social activities. Participants came together to celebrate, support, and remember loved ones. Families, friends, businesses, and organizations all joined to show compassion and encouragement.  Westchester Talk Radio was there, with host Andrew Castellano speaking with WHUD Radio personality Heather DeLuca to capture the energy and inspiration of the day.

Support Connection's Annual Support-A-Walk for Breast & Ovarian Cancer is community event dedicated to raising awareness about the needs of those living with breast, ovarian, or any gynecological cancer. The 2025 walk took place on Sunday, October 5, at FDR State Park in Yorktown Heights, NY, where everyone was invited to “Walk With Us, Wherever You Are.” The walk helps fund Support Connection's free and vital services, including one-on-one peer counseling, support groups, educational and wellness programs, and social activities. Participants came together to celebrate, support, and remember loved ones. Families, friends, businesses, and organizations all joined to show compassion and encouragement.  Westchester Talk Radio was there, with host Andrew Castellano speaking with Maid Brigade owner Robin Murphy to share stories of community support and inspiration from this meaningful event.

When Tongan woman Alisi Jack-Kaufusi was diagnosed with ovarian cancer at just 24-years-old, she was in disbelief. The subsequent surgeries and treatments have taken their toll, but, after seven years living with the disease, Alisi is passionate about sharing her story to help raise awareness of ovarian cancer and ensure it gets more resources into research, treatment and prevention.  This week's episode of Sistas, Let's Talk is a repeat of the show broadcast on 12th September 2024

This week on Health Matters, Courtney talks with Dr. Vivian Bea, Chief of Breast Surgical Oncology, and Dr. Evelyn Taiwo, a medical oncologist, at New York Presbyterian Brooklyn Methodist Hospital and Weill Cornell Medicine. For Breast Cancer Awareness Month, they discuss why breast cancer is on the rise among younger women, breast cancer risk factors, and the importance of screening. Dr. Bea and Dr. Taiwo also answer common questions about breast cancer, such as what age you can stop screening, and whether common items like deodorant or cell phones increase breast cancer risk.___Vivian Jolley Bea, MD, is Section Chief of Breast Surgical Oncology in the Department of Surgery at NewYork-Presbyterian Brooklyn Methodist Hospital. Dr. Bea received her masters degree in biology from Drexel University and her medical degree from Morehouse School of Medicine. Board certified in general surgery, Dr. Bea is an active member in numerous professional organizations, including the American College of Surgeons, American Society of Breast Surgeons, Society of Surgical Oncologists, and the Society of Black Academic Surgeons. Dr. Bea's areas of interest include breast cancer, benign breast disease, inflammatory breast disease, and high-risk management. She specializes in skin-sparing and nipple sparing mastectomies as well as oncoplastic breast conservation surgery. Dr. Bea is committed to community outreach, research, and eliminating breast cancer disparities.Dr. Evelyn Taiwo, MD, is a medical oncologist at NewYork-Presbyterian Brooklyn Methodist Hospital. She obtained her MD at Temple University School of Medicine in Philadelphia. Following her residency at Boston University Medical Center, she completed a three-year fellowship in hematology and oncology at the University of Texas Southwestern Medical Center in Dallas. Prior to joining Weill Cornell Medicine, Dr. Taiwo served as Assistant Professor of Medicine at the State University of New York, Downstate Medical Center in Brooklyn from July 2011-2019, and as Attending Physician and Site Director for the Hematology-Oncology Fellowship Program at Kings County Hospital. While at Kings County Hospital, she served in a leadership role as Director of the Breast Cancer Clinic, overseeing the operations, research activities, clinical care delivery, and education. As a researcher, Dr. Taiwo has contributed to a number of studies on cancer presentation in urban and minority patient populations.___Health Matters is your weekly dose of health and wellness information, from the leading experts. Join host Courtney Allison to get news you can use in your own life. New episodes drop each Wednesday.If you are looking for practical health tips and trustworthy information from world-class doctors and medical experts you will enjoy listening to Health Matters. Health Matters was created to share stories of science, care, and wellness that are happening every day at NewYork-Presbyterian, one of the nation's most comprehensive, integrated academic healthcare systems. In keeping with NewYork-Presbyterian's long legacy of medical breakthroughs and innovation, Health Matters features the latest news, insights, and health tips from our trusted experts; inspiring first-hand accounts from patients and caregivers; and updates on the latest research and innovations in patient care, all in collaboration with our renowned medical schools, Columbia and Weill Cornell Medicine.To learn more visit: https://healthmatters.nyp.org Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Please visit answersincme.com/YMJ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in gynecologic oncology discuss the evolving clinical roles of antibody–drug conjugates (ADCs) in ovarian cancer, focusing on CDH6-targeted ADCs. Upon completion of this activity, participants should be better able to: Identify the rationale for using antibody–drug conjugates (ADCs) in the treatment of platinum-resistant ovarian cancer (PROC); Evaluate the evidence for emerging CDH6-targeted ADCs in the treatment of patients with PROC; Outline expected clinical implications of the evidence for emerging CDH6-targeted ADCs in the treatment of PROC.

BUFFALO, NY - September 24, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on September 22, 2025, titled “Loss of Trp53 results in a hypoactive T cell phenotype accompanied by reduced pro-inflammatory signaling in a syngeneic orthotopic mouse model of ovarian high-grade serous carcinoma.” In this study, led by first author Jacob Haagsma and corresponding author Trevor G. Shepherd from the Verspeeten Family Cancer Centre and Western University, Canada, researchers investigated how the loss of Trp53 – a critical tumor suppressor gene – affects immune responses in ovarian cancer. The team found that deleting Trp53 led to more aggressive tumor growth and a weaker immune response. These findings help explain why some ovarian tumors may be resistant to immunotherapy and point to new ways to improve treatment. High-grade serous ovarian carcinoma (HGSC) is a deadly cancer that is often diagnosed at a late stage. Immunotherapy, which enhances the body's immune system to fight cancer, has shown limited effectiveness in treating this type of cancer. To better understand why, the researchers developed a mouse model that closely mimics human HGSC. They injected ovarian epithelial cells, with and without Trp53, into the fallopian tubes, the origin site of most ovarian cancers. “In this study, we developed a syngeneic model reflecting both the site of origin and the genotype of early HGSC disease by deleting Trp53 in mouse oviductal epithelial (OVE) cells.” Mice injected with cells lacking Trp53 developed faster-growing and more invasive tumors, reflecting how the disease typically progresses in humans. These tumors also had fewer active T cells, which are immune cells responsible for attacking cancer. Moreover, the T cells that were present appeared less capable of responding to the tumor, creating an immune environment that allowed cancer to grow uncontrolled. Further analysis revealed that tumor cells without Trp53 had reduced activity in genes related to inflammation. These changes were associated with lower levels of key proteins that normally help immune cells detect and attack tumor cells. When the researchers collected tumor cells from the abdominal fluid of the mice—a condition that simulates advanced-stage disease—they observed even lower immune signaling than before. This suggests that as the tumor spreads, it becomes better at evading the immune system. This study highlights how early genetic mutations can shape the interaction between tumors and the immune system. In particular, the loss of Trp53 appears to trigger a chain of events that weakens immune surveillance and accelerates tumor progression. These findings emphasize the need to consider both genetic mutations and the tumor environment when designing immunotherapies for ovarian cancer. Understanding how genes like Trp53 influence immune behavior may lead to more effective treatments and help identify which patients are most likely to benefit from immunotherapy. DOI - https://doi.org/10.18632/oncotarget.28768 Correspondence to - Trevor G. Shepherd - tshephe6@uwo.ca Abstract video - https://www.youtube.com/watch?v=WFQw0psuC3M Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28768 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Health & Fitness - World Ovarian Cancer Coalition

Today, I am honored to connect with Rachel Frankenthal, a board-certified physician assistant with a master's degree in public health, specializing in gynecologic oncology. Rachel is on the staff at UCLA Health, where she treats women with gynecologic cancers and women at high risk for uterine or ovarian cancer due to genetic mutations or a strong family history.  In our discussion, we unpack GYN oncology, covering the five GYN cancers, why ovarian cancer is the silent killer, and the labs and ultrasounds to help screen for ovarian cancer. We dive into genetics, including BRCA mutations and Lynch syndrome, appropriate genetic counseling, and what Rachel considers when dealing with younger patients still at peak fertility versus older patients. We explore the importance of HRT utilization for cancer previvors, the effects of pelvic radiation, vaginal and sexual health, and what thriving looks like after cancer. Rachel shares her stepwise approach to hot flashes, and we also discuss the importance of lifestyle, bone health, and specific research on the benefits of GLP-1s for women with ovarian and endometrial cancer.  This conversation is especially relevant as we are in GYN and Ovarian Cancer Awareness Month. I look forward to having Rachel back again, hopefully later this fall, to discuss the use of hormone replacement therapy with GYN oncology survivors. IN THIS EPISODE, YOU WILL LEARN: How the lack of effective screening makes ovarian cancer hard to detect due to  How BRCA and Lynch syndrome influence cancer risk and treatment choices The benefits of HRT for cancer previvors Risks that arise from surgical menopause without sufficient or properly dosed HRT Why less than 50% of eligible women actually receive hormone therapy How pelvic radiation impacts menopause, vaginal tissue, bladder, and GI health The support that is crucial for cancer survivors after pelvic radiation Lifestyle factors to improve cancer treatment outcomes   Rachel shares her stepwise approach to managing hot flashes  What GLP-1 research reveals about reducing ovarian cancer mortality and endometrial cancer risk Bio: Rachel Frankenthal Rachel Frankenthal is a board-certified and licensed Physician Associate and Menopause Society Certified Practitioner with a Master's in Public Health. She specializes in gynecologic oncology, treating women with gynecologic cancers as well as women at high risk for uterine or ovarian cancer due to genetic mutations. Rachel has a special passion for menopause and midlife women's healthcare. She developed the menopause clinic for gynecologic cancer survivors and previvors at UCLA and has played an integral role in developing the GYN cancer survivorship program, where she teaches the weekly yoga and meditation class. Rachel lectures at UCLA and across the country on the importance of comprehensive menopause care in cancer survivorship and has created a course on hormone therapy for gynecologic cancer survivors through the Heather Hirsch Academy. In addition to being a medical practitioner, Rachel is a certified yoga and Pilates instructor, a prior Broadway performer, and an advocate for integrative, holistic health. Connect with Cynthia Thurlow   Follow on X, Instagram & LinkedIn Check out Cynthia's website Submit your questions to support@cynthiathurlow.com Connect with Rachel Frankenthal On Instagram

Host: Mindy McCulley, MS Family and Consumer Sciences Extension Specialist for Instructional Support, University of Kentucky  Guest: Dr. Charles Dietrich, MD Associate Professor, Gynecologic Oncology, UK Markey Cancer Center and Medical Co-Director, Ovarian Cancer Screening Program Cancer Conversations Episode 67 During this episode of Cancer Conversations on Talking FACS, host Mindy McCulley sits down with Dr. Charles Dietrich, Associate Professor of Gynecologic Oncology and Medical Co‑Director of the Ovarian Cancer Screening Program at UK Markey Cancer Center.  They discuss the long‑running, free ovarian cancer screening effort across Kentucky. When discussing the Ovarian Cancer Screening program, a long-term research program, they address: who is eligible where screenings are offered how abnormal findings are managed, and barriers to participation. Dr. Dietrich reviews program outcomes — more than 50,000 women screened since 1988 with ~130 cancers detected, many at earlier stages with markedly better cure rates — and outlines future plans to refine screening with additional biochemical tests and expanded sites. Connect with the UK Markey Center Online Markey Cancer Center On Facebook @UKMarkey On X @UKMarkey

Marla Tellez returns for her 10th year as host of Kickin' Cancer — and this time, as a new mom. In this special installment of our mini-series, she sits down with Amy Cohen Epstein to reflect on a decade of championing women's health, the power of community, and the deeply personal reasons this cause continues to matter to her.Kickin' Cancer raises awareness and funds for the Lynne Cohen Foundation's national network of preventive care clinics: providing mammograms, genetic testing, counseling, and other lifesaving services to women at increased risk for breast and ovarian cancer.Register for Kickin' Cancer here: https://impact.lynnecohenfoundation.org/event/kickin-cancer-r-run-walk-stroll-2025/e686566Learn more about the Lynne Cohen Foundation here: https://lynnecohenfoundation.orgFor more, follow The Seam on Instagram, watch full episodes on Youtube, or visit the Lynne Cohen Foundation website.Produced by Peoples Media Hosted on Acast. See acast.com/privacy for more information.

Join host Madhavi sits down with Kaumudi Bhawe, Founder & Principal at YOM Consulting Services, for an exclusive conversation on Understanding Ovarian Cancer and Women's Health Advocacy. Often called the silent killer, ovarian cancer hides behind symptoms that are easy to miss, but awareness can change everything. In this interview, Kaumudi shares how ovarian cancer develops, what signs women should pay attention to, the role of genetics, how treatments have evolved, and why self-advocacy is one of the most powerful tools women have in their healthcare journey. This isn't just about information, it's about empowerment, healing, and amplifying women's voices in health.

On our podcast last year, Roxayn Elmer of Utah shared how her elderly mother beat Stage 4 ovarian cancer with cannabis therapy, low-dose chemo, and methylene blue. Recently, new scans showed a spot on her liver and active lymph nodes and doctors pushed for more chemo. Instead, Roxayn turned to cannabis oil suppositories, something she first learned about right here on this podcast. After three months, the latest scan showed no evidence of disease. Visit our website: CannabisHealthRadio.comFind high-quality cannabis and CBD + get free consultations at MyFitLife.net/cannabishealthDiscover products and get expert advice from Swan ApothecaryFollow us on Facebook.Follow us on Instagram.Find us on Rumble.Keep your privacy! Buy NixT420 Odor Remover

Send us a textI'm excited to introduce Irene—@irenieeweeniee—who turned a corporate layoff and months of misdiagnoses into a mission. After learning she had ovarian cancer, she started editing food videos on her phone and sharing her story on TikTok. What began as a way to cope became a platform for honest storytelling and women's healthcare advocacy.Irene's roots run through the SGV. Her immigrant parents ran a Thai restaurant, and weekends here taught her the hustle behind small businesses and where to find the real hidden gems. That perspective shapes everything she creates now: restaurant spotlights, must-try dishes, and a sprinkle of beauty content—always practical, upbeat, and community-minded.In this episode, we dig into how she navigated misdiagnosis, what helped her advocate for herself, and how she built momentum posting straight from a phone. We get tactical about consistency, captions, voiceover, and staying human on camera—plus how creators can responsibly shine a light on mom-and-pop restaurants across the San Gabriel Valley.If Irene's journey resonates, drop a comment with your SGV hidden gem and something you've learned from her content. Follow @irenieeweeniee, support the local spots mentioned, and subscribe for more SGV stories that connect food, family, creativity, and community.__________Music CreditsIntroEuphoria in the San Gabriel Valley, Yone OGStingerScarlet Fire (Sting), Otis McDonald, YouTube Audio LibraryOutroEuphoria in the San Gabriel Valley, Yone OG__________________My SGV Podcast:Website: www.mysgv.netNewsletter: Beyond the MicPatreon: MySGV Podcastinfo@sgvmasterkey.com

Guest Lori Cline - HCP 270On this episode Larry and Drew welcome very special guest and Drew's wife, Lori Cline. Lori will be speaking on Tuesday morning 9/30 at Mosaic Church in Memphis for a Ladies gathering. If you're already a part of the ReCharge conf, this is included in registration, but if you just want to come and hear Lori, ladies will be able to do that for only $25 per person (That price also includes the first session with Sam Rainer). On this podcast, Lori shares about life, marriage and ministry, but also gives an update on her health journey she's been facing this last year concerning Ovarian Cancer. To Register:https://bmaamerica.org/recharge/To see Lori's video devotionals go to:https://lifeword.org/media/?show=The+Lori+Cline+ShowSam RainerSamRainer.comChurchAnswers.comPrevious HCP Podcast with Sam:https://www.buzzsprout.com/835312/episodes/16295111Michael O'BrienMichaelO.orgYou can email us at info@healthychurchpodcast.com orTo find more information about The Healthy Church Podcast go to:http://www.healthychurchpodcast.comor find us on FaceBook!

A new blood test could dramatically improve survival rates for women with ovarian cancer by detecting it much sooner. The researchers tell us it's a game changer that could go on to save tens of thousands of lives around the world every year. Also: we meet the female Muslim jockey breaking new ground and inspiring the next generation. Khadijah Mellah has just made her amateur debut. Plus the woman who underwent a rare triple organ transplant talks about the joy of getting back to normal life; how a hand-cranked washing machine is saving thousands of people from hours of back breaking work; football's Homeless World Cup; and why a member of indie band Kasabian is opening a new music venue in a tiny Welsh town. Our weekly collection of inspiring, uplifting and happy news from around the world.

Alissa was diagnosed with Stage 4 Ovarian Cancer in January 2021 and despite the doctor's belief that she would never "get better", she was announced in " full remission" via Pet scan in June 2021. I have read everything I can get my hands on, including Dr. Kelly Turner's book, Radical Remission, which inspired me further in my belief that I could actually change the outcome of my life!   Alissa contributes her healing to my faith, spirituality and all of the integrative modalities she utilized on her quest for restoration including: diet change, adding supplements and individualized testing, detox through sauna and coffee enemas, red light therapy, yoga, mindfulness, hydration and many more!  Alyssa says she couldn't be more grateful for the integrative giants whose shoulders she is now standing on as she, too, has “survived cancer against all odds.”  The deeper she dives into this holistic world, the more confident she has become that our faith, our choices, and our community will indeed restore us to health and give us peace.   Get in touch with Allissa.... www.alissaperez.com Instagram @alissaperezpa Nasha Winters Stories That Heal Interview Nasha Winters Book, The Metabolic Approach to Cancer _____________ To learn more about the 10 Radical Remission Healing Factors, connect with a certified RR coach or join a virtual or in-person workshop visit www.radicalremission.com.   To watch Episode 1 of the Radical Remission Docuseries for free, visit our YouTube channel here.  To purchase the full 10-episode Radical Remission Docuseries visit Hay House Online Learning. To learn more about Radical Remission health coaching with Liz or Karla, Click Here Follow us on Social Media: Facebook  Instagram YouTube ____________

What if the most powerful cancer treatment costs nothing and has been hiding in plain sight for over a century?Join Dr. Katie Deming MD as she sits down with Dr. Nasha Winters, who survived terminal ovarian cancer at age 19 without conventional treatment. Dr. Winters now trains doctors worldwide in metabolic approaches that challenge everything we've been taught about cancer and healing.Dr. Deming brings her insider perspective from 20 years in conventional oncology, while Dr. Winters reveals why she accidentally discovered one of medicine's most suppressed healing tools. They examine the fascinating battle between two cancer theories that will completely change how you think about your health and why the losing theory from 100 years ago might hold the key to everything.Chapters:00:05:25 - Metabolic vs. Genetic Theories of Cancer00:15:14 - Stage 4 Ovarian Cancer at 1900:23:32 - Functional Medicine vs. Metabolic Approach00:34:44 - Fasting as a Healing Tool00:47:59 - The Future of Cancer CareIf you're overwhelmed by conflicting health advice, wondering why disease rates keep climbing despite medical "progress," or feeling like something crucial is missing from wellness conversations, this conversation cuts through the confusion. You'll discover Dr. Winters' systematic approach that identifies what's really driving illness in your unique body. Listen and learn about an ancient practice that modern medicine abandoned, one that could transform your relationship with healing forever. Metabolic Health Day Conference: https://metabolichealthday.life/WATCH on YOUTUBE: https://youtu.be/lOKhROiI-MgAccess the FREE Water Fasting Masterclass Now: https://www.katiedeming.com/the-healing-power-of-fasting/ Transform your hydration with the system that delivers filtered, mineralized, and structured water all in one. Spring Aqua System: https://springaqua.info/drkatieMORE FROM KATIE DEMING M.D. Work with Dr. Katie: www.katiedeming.comEmail: INFO@KATIEDEMING.COM 6 Pillars of Healing Cancer Workshop Series - Click Here to Enroll Follow Dr. Katie Deming on Instagram: https://www.instagram.com/katiedemingmd/ Watch on Youtube: https://youtube.com/playlist?list=PL5LplU70TE9i01tW_7Tozi8b6X6rGBKA2&si=ZXLy5PjM7daD6AV5 Please Support the Show Share this episode with a friend or family member Give a Review on Spotify Give a Review on Apple Podcast DISCLAIMER: The Born to Heal Podcast is intended for informational purposes only and is not a substitute for seeking professional medical advice, diagnosis, or treatment. Individual medical histories are unique; therefore, this episode should not be used to diagnose, treat, cure, or prevent any disease without consulting your healthcare provider.

Send us a textOvarian cancer, the second most common gynecologic malignancy, can be cured 90-95% of the time when caught early. Speaking of Women's Health Podcast Host talks through the risk factors like family history, BRCA gene mutations, obesity, and personal reproductive factors that are essential for early detection and prevention.• Risk increases with age (over 50), family history, and BRCA gene mutations• BRCA1 carriers face 35-70% lifetime risk compared to less than 2% in general population• Pregnancy, breastfeeding, and hormonal contraceptives reduce risk by decreasing ovulation• Tubal ligation, especially salpingectomy, dramatically lowers ovarian cancer risk• Common symptoms include abdominal swelling, urinary changes, bloating, early satiety• Regular pelvic exams and prompt reporting of symptoms are crucial for early detection• Ashkenazi Jewish women have ten times higher rate of BRCA mutations• Avoid using talcum powder near genital area as it's been linked to increased risk• Consider genetic counseling if strong family history exists• Prophylactic removal of tubes/ovaries after age 40 may be recommended for high-risk womenPlease follow the Speaking of Women's Health podcast wherever you listen to podcasts. Remember Be Strong, Be Healthy, and Be in Charge!Support the show

Shannon Miller is one of the most decorated American gymnasts in history, winning seven Olympic medals and becoming an icon of the 1990s gymnastics era. Beyond her success on the balance beam and floor, she faced one of her greatest challenges outside the gym. In 2011, Shannon was diagnosed with a rare form of ovarian cancer. After surgery and chemotherapy, she emerged cancer-free and has since dedicated herself to raising awareness about women's health. Today, Shannon will join us "On The Sidelines" to discuss her journey of resilience, reminding women to prioritize their health, and the importance of Biomarker Testing—which will be thoroughly explained by Professor and Director of Gynecologic Oncology at the James Comprehensive Cancer Center at The Ohio State University, Dr. David O'Malley.On the Sidelines is presented by OrthoCincy Orthopaedics & Sports Medicine.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

My returning guest is Olympic gymnastic champion Shannon Miller. We discuss some of the difficulties in preparing for and appearing in the Olympics, how she has dealt with transitioning away from competition, how she's dealt with ovarian cancer, and much more.

Nutritionist Leyla Muedin reveals the alarming increase in obesity-associated cancers in the United States over the past two decades. Highlighting findings from a recent study presented at the Endocrine Society's annual meeting, Leyla underscores the significant rise in cancer deaths linked to obesity, particularly among women, older adults, Native Americans, and Black Americans. She also explores the complex causes of obesity, including genetics, lifestyle, and environmental factors, and offers insights into effective weight management strategies. Additionally, Leyla examines the high rates of heart disease in various U.S. states, emphasizing the importance of lifestyle modifications and public health initiatives to combat cardiovascular diseases.

Today we’re joined by Carly Findlay — she’s an award winning writer, speaker, and an appearance and disability advocate. Carly was born with a rare skin condition called ichthyosis which is a rare genetic condition where the skin over produces dry, scaly, thickened skin and can be incredibly painful. Carly has spent much of her life navigating a world that hasn’t always made room for her differences. Carly has spoken widely about what it was like growing up, how she came to embrace the term “disabled” later in life, and the pressure to constantly explain or justify your body to other people and she has published two wonderful books titles ‘say hello’ and ‘Growing up disabled in Australia’ We also wanted to speak to Carly about a more recent challenge that she faced with her ovarian cancer diagnosis and what that has meant for her body now after going through early menopause and having a hysterectomy. We spoke about: What is was like growing up and having to face a lot of judgement and comments from strangers Why Carly decided to become an advocate for disabled people Laura being complacent with her ovarian cyst until Carly reached out and encouraged her to advocate for herself The early signs Carly experienced of ovarian cancer The confusing diagnosis Being faced with having to have either a half or full hysterectomy Having the choice of children taken away The additional things Carly had to navigate throughout treatment like chemo The ridiculous trolling Carly received like saying that she was ‘faking’ a cancer diagnosis The really practical ways you can support a loved one through a cancer diagnosis You can find more from Carly’s website You can follow Carly on instagram You can watch us on Youtube Find us on Instagram Join us on tiktok Or join the Facebook Discussion Group Tell your mum, tell your dad, tell your dog, tell your friend and share the love because WE LOVE LOVE! XxSee omnystudio.com/listener for privacy information.

Dr. Monica Prasad-Hayes explains GYN oncology, or treatment of gynecologic cancers. Dr. Hayes is an associate professor of OB-GYN, director of the GYN oncology fellowship at Mount Sinai Hospital, and a practicing GYN oncologist. She explains testing, treatment, and symptoms of ovarian cancer, cervical cancer, and more.

A recent Review discusses the epidemiology, risk factors, diagnosis, and treatment of ovarian cancer. William Cliby, MD, and John Weroha, MD, PhD, both from the Mayo Clinic in Rochester, Minnesota, discuss this and more with JAMA Associate Editor Margaret Wheeler, MD. Related Content: Ovarian Cancer Endometriosis Typology and Ovarian Cancer Risk Screening for Ovarian Cancer ----------------------------------- JAMA Editors' Summary